2CRSi SA | Finanzwire

PRESS RELEASE

published on 03/14/2024 at 08:00, 8 months 8 days ago

2CRSi announces the large success of its €12 million fundraising
2CRSi announces the successful €12 million fundraising from qualified and retail investors, providing resources for AI server sales. New shares to be traded on Euronext Growth Paris

Euronext Growth Paris Fundraising 2CRSi Retail Investors Qualified Investors
BRIEF

published on 03/13/2024 at 18:08, 8 months 9 days ago

2CRSi SA launches a major fundraising campaign to boost its growth in the Artificial Intelligence sector

Artificial Intelligence Fundraising 2CRSi Investment Energy Efficient Servers
PRESS RELEASE

published on 03/13/2024 at 18:03, 8 months 9 days ago

2CRSi SA: 2CRSi announces the launch of a €8 to €12 million round of financing to accelerate its growth in the Artificial Intelligence server market
2CRSi announces €8-€12 million round of financing to boost growth in AI server market, led by founder and CEO remarks on company's positioning and future goals

Artificial Intelligence Fundraising 2CRSi Round Of Financing Server Market
BRIEF

published on 03/12/2024 at 14:31, 8 months 10 days ago

2CRSi SA Updates on Voting Rights and Share Capital as of February 2024

Share Capital Voting Rights Regulatory Compliance 2CRSi SA February 2024
PRESS RELEASE

published on 03/12/2024 at 14:26, 8 months 10 days ago

2CRSi SA: Monthly information regarding the total number of voting rights and shares comprising the share capital as of February 29, 2024
2CRSi SA monthly report on voting rights and share capital as of February 29, 2024. Information according to French Commercial Code and AMF regulations

Share Capital Voting Rights French Commercial Code 2CRSi SA AMF Regulations
PRESS RELEASE

published on 02/22/2024 at 08:41, 9 months ago

2CRSi SA: Publication of consolidated financial statements from fiscal year 2023-2024
2CRSi announces publication of consolidated financial statements for fiscal year 2023-2024, setting ambitious sales targets and confirming sales acceleration. Strong financial position and new growth ambitions highlighted

Financial Statements 2CRSi Sales Targets Sales Acceleration Growth Ambitions
BRIEF

published on 02/22/2024 at 08:41, 9 months ago

2CRSi confirms its acceleration and sets ambitious goals

Sales Artificial Intelligence 2CRSi Finances Loans
BRIEF

published on 02/22/2024 at 08:41, 9 months ago

2CRSi announces its financial ambitions and consolidates its accounts for 2023-2024

Artificial Intelligence 2CRSi Finance Turnover Eco-Energy Technology
BRIEF

published on 02/21/2024 at 18:36, 9 months 1 day ago

2CRSi seals a major partnership in East Africa

Technology 2CRSi East Africa Data Center Cloud
PRESS RELEASE

published on 02/21/2024 at 18:36, 9 months 1 day ago

2CRSi SA: 2CRSi announces the signing of a memorandum of understanding (MOU) worth more than 12 million USD over 5 years with ICT Security Agency in East Africa
2CRSi announces the signing of a memorandum of understanding worth more than 12 million USD over 5 years with ICT Security Agency in East Africa for the deployment of a sovereign data center and training programs

2CRSi East Africa Data Center Memorandum Of Understanding ICT Security Agency

Published on 11/22/2024 at 18:45, 3 hours 10 minutes ago

CORRECTING and REPLACING the Not-So-Secret Lives of REAL "Mormon" Wives - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Published on 11/22/2024 at 16:00, 5 hours 55 minutes ago

Manimal Tales Unveils Two New Personalized Christmas-Themed Books to Spread Holiday Magic and Joy!
Published on 11/22/2024 at 15:55, 6 hours ago

Independent Proxy Advisory Firm ISS Recommends Signal Gold Shareholders Vote for Arrangement Resolution and Private Placement Resolution
Published on 11/22/2024 at 15:15, 6 hours 40 minutes ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Published on 11/22/2024 at 14:45, 7 hours 10 minutes ago

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

View all ACCESSWIRE

Published on 11/22/2024 at 18:14, 3 hours 41 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 18:00, 3 hours 55 minutes ago

Holding(s) in Company
Published on 11/22/2024 at 17:53, 4 hours 2 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 5 hours ago

EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 5 hours 55 minutes ago

Proposed cancellation of admission to trading

View all EQS

Published on 11/22/2024 at 14:35, 7 hours 20 minutes ago

Thales Press release
Published on 11/21/2024 at 06:58, 1 day 14 hours ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 2 hours ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 4 hours ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 4 hours ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024

View all LES ECHOS COMFI WIRE

News